Incyte Corp. is expecting clinical data later this quarter from a second pivotal study, TRuE-AD1, of its topical formulation of JAK inhibitor, ruxolitinib, in mild-to-moderate atopic dermatitis, and the company says it is committed to developing ruxolitinib cream as a first-line option for the condition.
The competitive pressure to become a contender in the atopic dermatitis market ticked up this week, with the US biotech announcing the bare bones of positive top-line clinical data from another